STOCKHOLM, Aug. 18, 2023 /PRNewswire/ — Continued strong momentum and promising signs of patient benefit in the combination study with fostrox and Lenvima® April – June Financial summary for the quarter Net turnover amounted to SEK 2.0 (0.5) million. The loss before interest, tax,…